This is a recording from the Cardiomyopathy UK 2022 Conference.
Our conference events bring together leading cardiomyopathy clinicians to present and respond to audience questions.
In this video Professor Elliott delivers a presentation on current and future therapies for cardiomyopathy. Professor Elliott and Trustee Libby Jarman then have a discussion, focusing on mavacamten. The floor is then opened for audience questions.
CHAPTERS:
00:00:05 - Presentation by Professor Perry Elliott
00:01:20 - Personalised medicine
00:05:04 – What we do at the moment
00:11:08 – Changing the paradigm
00:15:16 – Treating the underlying cause
00:18:18 – Gene therapy
00:22:22 – The new frontier
Discussion between Professor Elliott and Trustee Libby Jarman:
00:23:44 – Can mavacamten treat hypertrophic obstructive cardiomyopathy (HoCM)?
00:25:10 – Can you explain the results of the EXPLORER-HCM trial?
00:26:48 – Why did those with an identified genotype do better in the EXPLORER-HCM trial?
00:28:06 – Why did the treatment period with mavacamten in the EXPLORER-HCM trial only last 30-weeks?
00:29:10 – Will surgery continue to play a role in treating HCM?
00:30:29 – Will people with HCM be having surgery later in life?
00:31:14 – Could mavacamten stop someone who is gene positive for HCM from developing the disease?
00:32:21 – Will mavacamten be available on the NHS? If so, when?
00:35:26 – What can people do to increase the chance that mavacamten is made available on the NHS?
Audience Questions:
00:36:31 – What should I be lobbying my MP about in relation to DCM?
00:37:44 – Are you recommending that we lobby our MPs to make them more aware of cardiomyopathy and potential treatments?
00:39:08 – Are cardiomyopathies caused by viruses?
00:41:59 – Are there any new drugs on the way for ARVC? Are there any alternatives to amiodorone, but with less side effects?
00:45:28 – Is there any research showing a connection between stress and cardiomyopathy?
00:47:18 – What is the role of statins in cardiomyopathy?
00:48:35 – Are there contraindications with statins and calcium antagonists like diltiazem and verapamil?
00:49:12 – Are there any new therapies coming to the market for LVNC?
00:53:48 – How often should your genes be retested?
00:56:35 – Is it up to the patient to request that genes are retested, or is it an automatic process that is carried out when new genes are discovered for cardiomyopathy?
00:58:08 – Are viruses the only vehicle for genetic therapy? Are there any updates on synthetic lipid formulations?
Access free information, find out about support groups and speak with cardiomyopathy Specialist Nurses at www.cardiomyopathy.org
